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DOI: 10.1016/j.ajpath.2011.09.004CorrectionsIn the article entitled, “Distinct Expression Profiles of
p63 Variants during Urothelial Development and Bladder
Cancer Progression” (Volume 178, pages 1350–1360, of
the March 2011 issue of The American Journal of Pathol-
ogy), the third author’s name was listed incorrectly. The
correct name is Tian Huai Shen.
In the article entitled, “Abnormal Cell Properties and
Down-Regulated FAK-Src Complex Signaling in B Lym-
phoblasts of Autistic Subjects” (Volume 179, pages
66–74 of the July 2011 issue), the current address of
Hongen Wei was listed incorrectly. The current address
of Dr. Wei is the Mental Health Center, Shanghai Jiao
Tong University School of Medicine, Shanghai, China.
In the article entitled, “Spatiotemporal and Functional
Behavior of Airway Dendritic Cells Visualized by Two-
Photon Microscopy” (Volume 179, pages 603–609 of the
August 2011 issue), the first author’s name was listed
incorrectly. The correct name is Tibor Z. Veres.
In the article entitled, “Annexin 1 Released by Necrotic
Human Glioblastoma Cells Stimulates Tumor Cell Growth
2674through the Formyl Peptide Receptor 1” (Volume 179,
pages 1504–1512 of the September 2011 issue), the last
author’s surname was listed incorrectly. The correct sur-
name is Wang.
In the article entitled, “EMMPRIN Modulates Epithelial
Barrier Function through a MMP–Mediated Occludin
Cleavage Implications in Dry Eye Disease” (Volume 179,
pages 1278–1286 of the September 2011 issue), the last
author’s affiliation was listed incorrectly. The correct au-
thor affiliation is Fondation A de Rothschild, Paris,
France; and INSERM UMR S 968,** and the Institut de la
Vision, Paris, France; Université Paris 7,†† Diderot, Paris,
France.
In the article entitled “Selective Stimulation of
VEGFR2 Accelerates Progressive Renal Disease” (Vol-
ume 179, pages 155–166 of the July 2011 issue), part
of panel J was inadvertently omitted in Figure 2; the
figure appears correctly online (HTML and PDF ver-
sions). The corrected Figure 2 with legend appears on
the following page.
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Figure 2. Systemic overexpression of rAAV1-Flk-sel. A: Serum human VEGF-A concentrations in WT and eNOSKO mice treated with rAAV1-EV or rAAV1-Flk-sel
at 3 months (before UNx). B–E: Representative PAS staining of glomerulus at 3 months from WT mice treated with rAAV1-EV (B) or with rAAV1-Flk-sel (C) and
from eNOSKO mice treated with rAAV1-EV (D) or with rAAV1-Flk-sel (E). Flk-sel treatment did not change glomerular injury in either type of mouse at 3 months
(C and E), compared with control EV treatment (B and D), whereas eNOSKO mice exhibited mild mesangial expansion with either treatment (D and E). Scale
bar  20 m. F: Western blot for renal VEGFR2 in whole kidneys of WT and eNOSKO mice treated with rAAV1-EV or rAAV1-Flk-sel 1 month after UNx. G and
H: Quantitative analysis for VEGFR2 expression (VEGFR2/-actin ratio) (G) and phosphorylation (phosphorylated VEGFR2/total VEGFR2) (H). I: Western blot
for VEGFR1 expression and phosphorylation. J: Western blot for phosphorylated Akt. K: quantification of phosphorylated Akt. L: Representative photographs of
eNOSKO mice treated with rAAV1-EV or rAAV1-Flk-sel after UNx. *P  0.01; **P  0.05. Data are expressed as means  SD; n  10 in each group.
